OM85
- Generic Name
- OM85
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children with Recurrent Wheezing
- Conditions
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- OM Pharma SA
- Target Recruit Count
- 288
- Registration Number
- NCT05857930
- Locations
- 🇺🇸
Arizona Medical Clinic, Phoenix, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸The University of Arizona Medical Center - University Campus, Tucson, Arizona, United States
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- OM Pharma SA
- Target Recruit Count
- 525
- Registration Number
- NCT05677763
- Locations
- 🇩🇪
Ludwig Maximilians Universität München, München, Bayern, Germany
🇩🇪Praxiszentrum Triftplatz - Pediatrics, Schönau Am Königssee, Bayern, Germany
🇩🇪Medizinische Hochschule Hannover, Hanover, Niedersachsen, Germany
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- OM Pharma SA
- Target Recruit Count
- 63
- Registration Number
- NCT05222516
- Locations
- 🇩🇪
Hautarztpraxis Burgstrasse, München, Germany
🇩🇪MENSINGDERMA research GmbH, Hamburg, Germany
🇫🇷Centre d'investigation clinique GHE, Bron, France
Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Franciscus Gasthuis
- Target Recruit Count
- 500
- Registration Number
- NCT05063149
- Locations
- 🇳🇱
Franciscus Gasthuis & Vlietland, Rotterdam, Zuid-Holland, Netherlands
Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Fang Deng
- Target Recruit Count
- 83
- Registration Number
- NCT05044169
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
- Conditions
- Interventions
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 395
- Registration Number
- NCT04129931
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of California San Diego: Airway Research & Clinical Trials Center, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Vifor Pharma
- Target Recruit Count
- 179
- Registration Number
- NCT03047954
Prevention of OM-85 on Bronchiectasis Exacerbation
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 196
- Registration Number
- NCT01968421
- Locations
- 🇨🇳
Shanghai Tongji University, Shanghai, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.